Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology

Rivera, Lina María Saldarriaga; Fernández-Ávila, Daniel G.; Molano, Wilson Bautista; Jaramillo-Arroyave, Daniel; Ramírez, Alain Jasaf Bautista; Maldonado, Adriana Díaz; Izquierdo, Jorge Hernán; Jáuregui, Edwin; Muñoz, María Constanza Latorre; Restrepo, Juan Pablo; Charry, Juan Sebastián Segura

doi:10.1016/j.rcreue.2020.10.001

Cited by 3 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28,30,31 Tampoco se encontraron diferencias en cuanto al género y la hospitalización por Covid-19, no obstante la edad de las mujeres es mayor a la de los hombres, y la patología prevalente es la Artritis Reumatoide (AR) que es la enfermedad del EIMI con más secuelas pulmonares lo que podría explicar el peor pronóstico frente a la enfermedad, ya que el 100 % de los fallecimientos fueron mujeres. [32][33][34] La incidencia de hospitalización en nuestro estudio, no mostró diferencias significativas entre las especialidades, aunque fue mayor en los pacientes de reumatología, coincidiendo con los datos aportados por otros autores. 35 Además, comparando los resultados con la población de referencia, se ha observado mayor tasa de hospitalizaciones por Covid-19 en los pacientes afectados por EIMI reumáticas, esto podría estar relacionado con los tratamientos biológicos o biosimilares que se utilizan para estas patologías.…”

Section: Discussionunclassified

Características clínicas de los pacientes con enfermedades inmunomediadas inflamatorias afectados por Covid-19

et al. 2022

View full text Add to dashboard Cite

Objetivo principal: Describir la incidencia de Covid-19 por sexo y especialidad en pacientes con Enfermedad Inmunomediada Inflamatoria (EIMI). Metodología: Estudio observacional prospectivo de pacientes en seguimiento/tratamiento en un Centro de Enfermedades Inmuno-mediadas Inflamatorias, de marzo a junio de 2020. Resultados: El total de pacientes en seguimiento era de 1672, se realizaron 3480 consultas, siendo telemáticas 2382(68.4 %). Se confirmaron 77(4.60 %) casos de Covid-19, siendo mujeres 40 (51.98 %). Los síntomas prevalentes fueron: tos seca (81.8 %), mialgias/artralgias (77.9 %), cefalea (68.8 %), fiebre (55.8 %) y neumonía (22.4 %). Se encontraron diferencias en los síntomas por especialidad: mialgias/artralgias (p=0.001), cefalea (p=0.011), fiebre (p=0.012). Necesitaron hospitalización 17 pacientes (22.10 %) y 3 (17.65 %) en Cuidados Intensivos. Conclusión: La terapia con fármacos biológicos no se asoció con peores resultados de Covid-19. Las consultas telemáticas realizada por Enfermeras de Práctica Avanzada garantizaron el seguimiento óptimo, la detección precoz y la continuidad del tratamiento.

show abstract

Section: Discussionunclassified

Características clínicas de los pacientes con enfermedades inmunomediadas inflamatorias afectados por Covid-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Once again, this finding raised questions about the safety of using antimalarials, especially in patients with increased cardiovascular risk. Likewise, this concern caused antimalarial treatment for patients with autoimmune diseases to be suspended, and this generated a higher frequency of disease relapses (Saldarriaga Rivera et al, 2020;Egeli et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?

Santos-Moreno¹,

Ibatá²,

Martínez³

et al. 2023

Front. Drug Saf. Regul.

View full text Add to dashboard Cite

Introduction: The antimalarials chloroquine and hydroxychloroquine have been used for several decades in treating malaria and some autoimmune diseases—mainly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)—with excellent efficacy and safety. Due to the massive use of antimalarials worldwide for managing SARS-CoV-2/COVID-19 infection during the last 2 years and the consequent increase in cardiac arrhythmia, fear has risen about the safety of using antimalarials, especially for patients with increased cardiovascular risk.Objective: To describe a real-life experience about the safety of antimalarials in the setting of a single rheumatological center in Colombia.Methods: This is a cross sectional study that includes patients diagnosed with RA and treated with antimalarials between 2020 and 2021. Clinical follow-up information was gathered from the medical records, and all reported adverse events were described.Results: A total of 957 patients were included, primarily women (79.2%). The most frequent comorbidities were hypertension and osteoporosis. Chloroquine use was more frequent than hydroxychloroquine (86.4% vs. 13.6%). During the observation period, 243 (25.4%) patients presented at least one adverse event, 72 (29.6%) had retinal toxicity, 85 (35%) dermatological events, and 81 (33.3%) gastrointestinal intolerance. Other adverse events reported less frequently (15.2%) included headache, dizziness, lipothymia, and elevated transaminases. There were no reports of cardiovascular events from the period of antimalarial use to the date of data collection despite the high frequency of previous metabolic or cardiovascular disease in this cohort.Conclusion: This study reasserts the evidence of antimalarials safety profile for patients with rheumatological conditions such as RA. RA patients that were treated with antimalarials at doses recommended by the guidelines had no cardiovascular events.

show abstract

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Насонов

Лила

Мазуров

et al. 2021

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.

show abstract

Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology

Cited by 3 publications

References 62 publications

Características clínicas de los pacientes con enfermedades inmunomediadas inflamatorias afectados por Covid-19

Características clínicas de los pacientes con enfermedades inmunomediadas inflamatorias afectados por Covid-19

Adverse events in rheumatoid arthritis patients under antimalarial treatment—Is there cardiovascular compromise?

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Contact Info

Product

Resources

About